Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma

While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCF(Skp2)) promotes proteasomal degradation of the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, E, Abdel-Malek, M A Y, Jagannathan, S, Vad, N, Karns, R, Jegga, A G, Broyl, A, van Duin, M, Sonneveld, P, Cottini, F, Anderson, K C, Driscoll, J J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339431/
https://www.ncbi.nlm.nih.gov/pubmed/27677741
http://dx.doi.org/10.1038/leu.2016.258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339431/
https://www.ncbi.nlm.nih.gov/pubmed/27677741
http://dx.doi.org/10.1038/leu.2016.258

Ejemplares similares